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The Golden Jubilee of vaccination
against poliomyelitis
Jonas Salk (1914-1995) in India in 1983 to receive the Jawaharlal Nehru Award.
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Inactivated poliovirus vaccine (IPV), developed in the USA by Jonas Salk in the early 1950s, was
field tested in 1954, and found to be safe and effective. The year 2004 marks the golden jubilee
of this breakthrough. From 1955 IPV was used extensively in the US and polio incidence declined
by more than 95 per cent. However, in 1962, when oral poliovirus vaccine (OPV) became available,
the national policy was shifted to its exclusive use, for reasons other than science and economics.
The World Health Organisation (WHO) also adopted the policy of the exclusive use of OPV in
developing countries. Thus IPV fell into disrepute in much of the world, while Northern European
countries continued to use it. New research led to improving its potency, reducing its
manufacturing costs and combining it with the diphtheria-tetanus-pertussis (DTP) vaccine to
simplify its administration and reduce programmatic costs. All countries that chose to persist
with IPV eliminated poliovirus circulation without OPV-induced polio or the risk of live vaccine
viruses reverting to wild-like nature. IPV is highly immunogenic, confers mucosal immunity and
exerts herd protective effect, all qualities of a good vaccine. It can be used in harmony with the
expanded programme on immunization (EPI) schedule of infant immunisation with DTP, thus
reducing programmatic costs. During the last ten years IPV has once again regained its popularity
and some 25 industrialised countries use it exclusively. The demand is increasing from other
countries and the supply has not caught up, leaving market forces to dictate the sale price of
IPV. Anticipating such a turn of events India had launched its own IPV manufacturing programme
in 1987, but the project was closed in 1992. Today it is not clear if we can complete the job of
global polio eradication without IPV, on account of the genetic instability of OPV and the
consequent tendency of vaccine viruses to revert to wild-like properties. The option to use IPV
is complicated since it is not yet licensed in India, we do not manufacture it and imported vaccine
would be prohibitively costly. However, in this golden jubilee year we have much to celebrate as
the global eradication of wild polioviruses is within sight. Had we strictly followed the principles
of science and health economics, perhaps we could have achieved success earlier and cheaper,
with the absence of vaccine-induced polio as the bonus.
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The twin purposes of this review are to celebrate the
fiftieth year of vaccination against polio and to pay tribute
to the scientist who developed the first safe and effective
poliovirus vaccine. The innocuity and immunogenicity of
the inactivated poliovirus vaccine (IPV) was established in
humans (after animal studies) by Jonas Salk in 1952 and
19531,2. Thereafter a massive field trial for determining its
protective efficacy was conducted in 1954, which involved
over a million subjects1,2. It confirmed the safety and
efficacy of IPV and 2004 is the fiftieth anniversary (golden
jubilee) of this breakthrough. IPV was licensed for general
use in the USA in 1955. India honoured Salk with the
Jawaharlal Nehru Award for International Understanding
in the year 1983.
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2By 1959 Albert Sabin succeeded to attenuate the three
serotypes of polioviruses after years of arduous and
diligent research, thus developing the live oral poliovirus
vaccine (OPV)3. Within a decade of these developments,
several nations used either IPV or OPV or both in
combination and successfully controlled or even eliminated
polio from their territories. From those beginnings of
human mastery over polioviruses and poliomyelitis, the
world has progressed much towards eradicating them
from humans altogether. This review will focus on the
first vaccine namely IPV. A treatise on IPV will be
incomplete without noting the contribution of Anton van
Wezel, the Dutch scientist who improved and standardised
the production and potency of IPV4. This review should
help dispel some misconceptions that had arisen over the
years regarding certain properties of IPV.
Unfortunately, none of the three scientists who
developed these vaccines is alive to celebrate with us
the impending global victory over polio. As we are nearing
the global eradication of wild polioviruses, the need and
prospects of IPV to complete it will also be explored.
Successful interruption of wild virus transmission and
the safe and scientific management of the final phase of
eradication to avoid the risk of polio due to vaccine
viruses, are the best tributes we can pay to the memory
of Salk, Sabin, van Wezel and a number of others who
made these achievements possible.
The development of IPV by Salk : The incidence of
polio in the USA began increasing perceptibly from about
1916, when the endemic ‘infantile paralysis’ of infants
and preschool children transitioned into ‘epidemic polio’
affecting children and adolescents, and occasionally even
adults5. Franklin D Roosewelt was 39 yr old in 1921
when he developed polio paralysis in both lower limbs5.
In spite of this physical challenge he was elected
President of the USA in 1933. In 1938 Roosewelt’s
friend and former partner in a law firm, Basil O’Connor,
established the National Foundation for Infantile Paralysis
(NFIP), which grew to become one of the most
successful voluntary associations ever, dedicated to a
health problem5,6. The NFIP raised money from and
through a multitude of ordinary people, especially
housewives who went house-to-house in annual
campaigns of collection that was cleverly called “March
of Dimes”. It built up a huge network of volunteers for
local activities. The funds were used to pay for the costs
of treatment and rehabilitation of polio affected persons,
to train nurses and physical therapists to care for them
and also to conduct laboratory research to understand
more about the virus and eventually to develop vaccines
against polio. The funds for research on polio from the
NFIP during 1940s and 1950s were an order of
magnitude larger than that disbursed by the National
Institute (presently Institutes) of Health (NIH), which
had access to governmental allocations, but had other
priorities5.
In 1947 Jonas Salk joined the University of Pittsburg,
in Pennsylvania State, as Associate Professor of
Microbiology. He was born in New York in 1914 to
parents who had migrated from Russia. After graduating
in Medicine in 1939, he worked with Thomas Francis Jr.
in Ann Arbor, Michigan, from 1941 to 1947, the main
avenue of research being the cultivation (in fertilized hens’
eggs) and inactivation of influenza viruses to make
vaccines for use by the defence forces.
By 1948 three serotypes of polioviruses had been
identified by cross neutralisation experiments in
monkeys5. Research to check if there were more than
three serotypes was initiated and funded by NFIP. Four
laboratories including Salk’s laboratory in Pittsburg were
selected to type a large number of poliovirus isolates to
search for unknown type. The plan was to do all the
tests in monkeys, since there was no other established
method to type the viruses. Infecting monkeys with a
known type, waiting for them to recover and to challenge
them with untyped strains was slow, laborious and
expensive. In 1949 John Enders, Thomas Weller and
Frederick Robbins grew polioviruses in human non
nervous system cells cultured in laboratory glassware7.
They shared the 1954 Nobel Prize for this breakthrough
work. Salk saw the immense potential of using cell culture
system to type strains of polioviruses fast and cheap and
also to grow them in large enough quantities to attempt
to make a killed vaccine5. The then widely held view of
experts was that an infectious vaccine would be necessary
to protect against polio3,5,6. Salk knew immunology well
enough to predict that actual infection was unnecessary
to induce immunity, but injections of killed virus antigen
would suffice. He pursued his experiments at relentless
pace and proved the principle of immunogenicity and
safety of killed virus preparation, first in animals and
later in human subjects, in 1952 and 19531,2,5.
The vaccine field trial and licensure: The epidemic of
polio in the US in 1952 claimed more than 58,000 victims
and in 1953 the incidence was 20 per 100,000 population,
the highest ever recorded in the US5,6. There was great
urgency in the minds of O’Connor and Salk to develop
and deploy a safe and effective vaccine to prevent
continued devastation by the virus5. As stated earlier,
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3the then prevalent opinion of most poliovirus experts,
including Sabin, was that only a live attenuated virus
vaccine would be effective against polio, as it is due to
an infection that begins on the pharyngeal and intestinal
mucosa and later spreads to the spinal cord5,6. Jenner’s
smallpox vaccine, Pasteur’s rabies vaccine and Theiler’s
yellow fever vaccine – all contained live viruses. Salk
was convinced that an inactivated vaccine would work
just as well as in the case of influenza. By January 1953
Salk had given one or another version of his killed virus
vaccine to 161 persons without incident5.  He
demonstrated not only the development of virus
neutralising antibodies but also that the level of induced
antibody after three doses of IPV was often higher than
what was obtained after natural infection5,8.
The NFIP went ahead and organised what became
one of the largest ever vaccine trials, directed by Thomas
Francis Jr., a most trusted and respected epidemiologist
of his time5,6. The trial participants included 1,829,916
children in different parts of the USA and also in Canada
and Finland6. The experiment involved both placebo
controls and in some areas observed controls5,6. On April
12, 1955 Francis announced the result of the trial in a
public function organised jointly by the NFIP and the
University of Michigan (where the Vaccine Evaluation
Centre functioned under Francis)5,6. It also turned out to
be a big ‘media event’. The protective efficacy was
80-90 per cent against paralytic polio9. The success of
the trial confirming the safety and efficacy of the vaccine
was publicised widely by the media in the US and
Europe5. The very same day Ovetta C. Hobby, the US
Secretary of Health, signed the papers to license the
vaccine for general use5. These historical details are
essential to highlight some issues that have relevance to
the subsequent unfolding of the history of the two
vaccines, IPV and OPV.
What is worth noting is that research leading to the
development of the vaccine and its field trial were funded
entirely by the NFIP, a private voluntary organization.
The vaccine trial was also conducted in the private
voluntary sector. The Foundation’s volunteers, alumni
of NFIP-supported training programmes, members of
Parent-Teacher Associations, and State health officers
made the field activities of the vaccine trial possible.
The Federal government or its agencies such as the NIH
or the Communicable Disease Center (CDC, presently
the Centers for Disease Control and Prevention) were
not involved in either the development or the field trial of
the vaccine (except for quality check of the vaccine by
the Laboratory of Biologics Control under NIH). During
the crucial years of Salk’s intense experiments, he wrote
only very few scientific papers for publication1,2,8,10.
Much of the detailed experiments were not written up
for peer reviewed, publications and critique by fellow
scientists, as would have been expected of any scientist
generating new data and creating new information5. On
the other hand, the NFIP had regular Round Table review
meetings of all research funded by it, thus giving Salk
the opportunity to present his many studies in detail to a
select group of scientists and managers5. Even the
vaccine trial results were announced directly to the public
and the media, a move that was much misunderstood as
sheer publicity seeking. To top it all, Salk became a public
hero both in the US and globally. All these seem to have
alienated several mainstream polio scientists and officials
of the Federal government agencies, many among whom
were ardent believers of the popular hypothesis that only
a live attenuated vaccine would be effective against
polio5,6. Indeed, when Sabin’s live oral vaccine became
available, by about 1962, the Public Health leaders
promptly adopted it for immunisation, as if they were
embarrassed of the killed vaccine.
The negative attitude of the leading scientists was
clear from the fact that Salk was never elected to the
National Academy of Sciences of the USA5. However
Salk did get a Congressional medal and a citation from
US President Eisenhower as the nation’s appreciation.
These were recognitions in the political rather than in
the science arena5. The only two major awards he was
given in the US were the Albert Lasker Award of the
American Public Health Association and the Bruce
Memorial Award of the American College of Physicians.
The “Cutter incident” and incompletely inactivated
vaccine: For preparing the vaccine for trial, polioviruses
were grown in cell cultures at the Connaught
Laboratories of the University of Toronto, Canada, and
shipped to two US manufacturers, the Park Davies and
Co. in Detroit, and Eli Lilly and Co. in Indianapolis5. They
inactivated the viruses, filtered and blended the three
types into the vaccine for the trial. Samples from every
production batch was tested for absence of residual live
virus by the manufacturer, the Laboratory of Biologics
Control (LBC) of the NIH in Bethesda and Salk’s own
laboratory. The vaccine preparation was exactly as
prescribed by Salk10. The seed viruses were type 1
Mahoney, type 2 MEF-1 and type 3 Saukett strains6-10.
The viruses were inactivated with formaldehyde 1:1000
for 13 days at 37ºC10. After the vaccine was licensed,
four additional companies also began manufacturing IPV,
using supposedly the same protocol as had been approved
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4by Salk and the NFIP. However, when it was licensed
for production there was no government regulation in
place for safety testing5. All manufacturers had sent their
vaccines to the LBC for safety tests, but they could sell
the vaccine even prior to the completion of safety tests
at the LBC. One of the new manufacturers was the
Cutter Laboratories in Berkeley, California 5.
The staff of LBC was overworked and could not cope
up with the volume of work with the necessary speed to
complete safety tests prior to the distribution of vaccines11.
The vaccine samples had to be injected in monkeys to
ensure safety; although tests in cell cultures would have
been simpler, that method had not yet become routine in
the LBC. The vaccine made by Cutter Laboratories was
ready for marketing immediately after licensing, indicating
that they had worked on vaccine manufacture even while
the francis trial was going on. In LBC, the Cutter vaccine
caused paralysis in monkeys and the microbiologist
Bernice Eddy reported the matter to William Sebrell, the
Director of NIH11. He chose to ignore the information
and the Cutter vaccine was not withheld from release as
it should have been, based on the safety problem identified
in the NIH1. Two weeks later, reports of children
developing polio after taking the Cutter IPV began coming
in. Within days, the Surgeon-General instructed the
withdrawal of IPV made by Cutter. About two weeks
later use of IPV from all other manufacturers was also
suspended for completion of safety checks and finding
them safe, immunization was resumed5. Sebrell was held
incompetent to handle the situation and had to resign
later11. James Shannon was given charge of managing
the Cutter episode and he and O’Conner sharply disagreed
on the management, of the problem11. After Sebrell’s
resignation, Shannon was made the Director of NIH.
According to the new NIH Director, “it was the forceful
personality of O’Connor with the political support he had
that was able to override some of the essential details of
Federal management of an important biological
product”11. Even the Secretary of Health, Ovetta C.
Hobby, had to step down on account of the Cutter
incident, the way it was handled, and the embarrassment
caused by it5,11.
The whole Cutter episode lasted for less than two
months. Obviously the Cutter Company had made two
errors-they had compromised on the manufacturing
process and also on safety testing. Based on this
experience a Technical Committee developed safety
regulations for the production of the vaccine, to be
implemented by the companies under the authority of
the LBC of NIH5,11. The new vaccine  regulations altered
some steps of vaccine production, apparently resulting in
some reduction in antigenic potency9.
The Cutter vaccine indeed had residual live virus, which
was the cause of polio in vaccinated monkeys and children
and in family contacts and playmates of vaccinated
children. A new Poliomyelitis Surveillance Unit was
created in the CDC in Atlanta, which investigated the
vaccine-related polio cases and concluded that
79 vaccinated children, 105 family members and
20 community contacts had developed polio due to the
virus contained in the vaccine5. Among them, 192 had
paralysis6,12. It was in this unfortunate manner that two
of the Federal agencies ultimately got involved with issues
related to IPV. The Cutter incident did dent the public’s
confidence in IPV for a short while, but with the continued
use of quality-assured vaccine, it became popular once
again among the public. But the unpleasantness among
scientists and Federal agencies seems to have persisted,
based on the facts enumerated above. As soon as OPV
became available, the American Medical Association
recommended it for regular use in the country5. The
Federal government and the American Academy of
Paediatrics welcomed this shift. That OPV caused more
cases of paralysis globally every year than those caused
by the faulty Cutter vaccine, received scant attention from
Public Health leaders or was ignored by them, apparently
partly on account of their faith in and fascination for the
first effective oral live virus vaccine, but also partly due to
their displeasure of Salk and his IPV.
There are important lessons India must learn from this
episode and how it was handled. First, when a problem
arises, its solution must include both short-term and long-
term interventions. If one vaccine from a manufacturer
failed in quality, other vaccines could also fail. Therefore,
a National Regulatory Authority was established to ensure
the safety of vaccines and that idea has since been
accepted universally. Secondly, since the polio vaccine
resulted in the disease it was intended to prevent,
surveillance of the disease in order to detect any more
such cases was instituted. This was instrumental in
detecting the vaccine-associated polio when OPV was
introduced13. Thus every unexpected problem has the seed
of the opportunity to make progress beyond the mere
solution of the problem. It seems that in our country, punitive
rather than corrective interventions are given importance
when something goes wrong. For example, in 1974 the
Government of India ordered the closure of India’s first
and only successful OPV manufacturing unit (at the
Pasteur Institute in Coonoor, Tamil Nadu) just because
one vaccine candidate batch of type 3 poliovirus did not
pass the quality test. Earlier six batches of trivalent OPV
had been passed and also released by the Pasteur Institute.
Since then India had to import all necessary OPV from
other countries.
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US, stray cases of polio were observed  within the
incubation period of its administration to children13.  A
Special Advisory Committee was appointed by the
Surgeon-General of the USA to investigate if the disease
was caused by the vaccine13. The Committee reported
on the risk of paralytic polio due to Sabin vaccine in
comparison with that of disease in the absence of
immunization, and concluded that the benefit justified the
risk13. The Committee did not report on the comparative
risk-benefit assessment of the two vaccines, or in other
words, it ignored the very existence of IPV13. This piece
of information seems to confirm the apparent animosity
towards IPV, which had unfortunately developed on
account of all the reasons stated earlier. These extraneous
factors, rather than scientific or economic arguments
seem to explain why the Public Health leaders of the
US switched to OPV as soon as it became available,
and for their unfortunate persistence with it for more
than three decades in spite of the fact that it caused
polio in 8-10 children every year. Finally in 1996 the US
reversed its stand and went back to IPV14. By then the
US had influenced the rest of the world to believe that
there was something wrong with IPV.
The application of biotechnology to improve IPV: Salk
did as much as he could do to make a safe and effective
vaccine against polio. Once the vaccine was introduced,
quite understandably the NFIP was no longer able to
raise as much funds as before. As IPV was a product of
NFIP, and as OPV became popular, no one in the USA
seemed to be scientifically interested in further research
to improve on it. However, there were other nations loyal
to Salk IPV, such as Finland, Sweden, Norway,
Netherlands and Francophone parts of Canada. Finland
and Canada had participated in the Francis trial of IPV in
1954 and found it to be completely safe and highly
effective6. In 1961 Finland gave IPV in a nationwide
campaign and eliminated wild virus polio without the risk
of vaccine-virus polio of OPV15,16. Norway used IPV
from 1961 to 1969 and had eliminated polio17. When
OPV became available, Norway switched to it, believing
it to be superior. During the next ten years OPV-induced
polio was recognised at a rate of one case per 400,000
vaccinated subjects and in addition one case among
unvaccinated contacts per 100,000 vaccinees17 .
Consequently Norway reverted to the exclusive use of
IPV in 197917. Thus, IPV remained or became the vaccine
of choice in the Scandinavian and other North European
countries. Research to improve IPV was spearheaded by
scientists in the Netherlands and France.
Until about the early 1980s IPV continued to be made
the way Salk had prescribed10. There were two problems
to be addressed if it were to be improved. One, the viruses
had to be grown on monolayer cell cultures. The method
was slow, cumbersome and did not yield large amounts
of vaccine per batch. unlike the live vaccine, which is
also made in cell culture, there was much loss of the
antigen content with virus inactivation, resulting in the
final product remaining relatively more expensive,
compared to the live vaccine. Second, the vaccine was
not properly standardised for its potency, for which reason
there was much variation between products and batches.
The IPV used in Finland had low potency of the type 3
component, resulting in immunity gap and an outbreak
of polio due to type 3 wild virus affecting vaccinated
children, more than a decade after it was eliminated18.
In the Netherlands, the Rijks Institute (popularly
known as RIVM) in Bilthoven made IPV for the country,
but it had no commercial interests. Their biomedical
engineer van Wezel realised that cell cultures could be
adapted to large-scale production, just like bacteria, in
controlled bioreactors, usually called fermenters19 .
Mammalian cells would require a surface on which they
had to attach before cell division could take place, unlike
bacteria (and some cells) that grow in suspension. The
bioreactor was an excellent system to mass-produce cells
that grow in suspension. So van Wezel used minute
spheres, called microcarriers, on which the mammalian
cells would attach and the rest of the process was like in
suspension culture in bioreactors19. The cells on
microcarriers could be infected with polioviruses. He
grew polioviruses in 1000 litre bioreactors and established
sophisticated concentration and purification processes
and this new system could produce one to two million
doses per production batch20. This new IPV had higher
potency than the earlier Salk vaccine. The immunogenic
potency of IPV is measured as D antigen units. The
potency of old IPV varied between manufacturers and
batches, and on the average contained 20, 2 and 4 D
antigen units of type 1, 2 and 3 polioviruses per dose.
The new product of van Wezel was made with 40,8 and
32 D antigen units per dose20,21. The final vaccine
contained virtually no extraneous protein and the nucleic
acid from the cell substrate was only in picogram quantity.
The vaccine safety test in monkeys could be replaced
with that in cell cultures22. The antigen potency test in
monkeys was also replaced with test in rats and cell culture
virus neutralisation with enzyme immunoassays23. French
researchers showed that Vero cells, a continuous cell line
of simian origin, was safe for human vaccine production
and monkeys could thus be removed from use to produce
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6or quality test IPV24,25. On the other hand, most OPV
manufacturers use approximately 50-60 monkeys, moslty
Indian Rhesus (Macaca mulatta), to manufacture and
quality test every batch of OPV that we continue to import
and use in our country, even though such use of monkeys
is banned within India.
The innovations described above led to markedly
reduced cost of production of this highly purified and
potent vaccine24-26. The Dutch scientists also showed that
IPV could be combined with diphtheria-tetanus-pertussis
(DTP) vaccine, making its injections harmonised with
that of the usual infant vaccination under the expanded
programme on immunization (EPI). By all counts this
new formulation IPV was perfectly suited for use in
developed as well as developing countries25-27. The
advantages were complete safety, excellent
immunogenicity after 2 or 3 doses, combinability with
DTP and harmony with EPI schedule, markedly lower
cost of production than the old IPV and reduced
programmatic costs of immunisation. Our studies in
Vellore (see below) raised the hope of introducing it in
India at least on a limited scale for learning some field
experience with it in the country, for which purpose the
manufacturer was willing to sell this IPV for about ten
rupees a dose. The reason for not using this new IPV in
developing countries like India was not based on science
or economics, but apparently on personal prejudices of
policy makers.
Two manufacturers in France and Canada made (and
continue to make) this new IPV for commercial
distribution and it has become very popular in
industrialised countries25,28. We had the opportunity to
investigate its immunogenicity soon after it was made
and we named it as ‘IPV of enhanced potency’ (IPVe or
E-IPV)29,30. Since only E-IPV is currently available in
the market, the term IPV will hereafter mean this new
vaccine. The original Salk IPV will be refferred to as
‘old IPV’ or ‘Salk vaccine’.
Immunogenic efficacy of IPV: The 1954 Salk vaccine
trial by Francis had found that the protective efficacy of
different batches of IPV correlated with the potency of
vaccine, which was measured by antibody response in
children, in other words, its immunogenicity6. On the
average, the vaccine efficacy in the trial was 80-90
per cent against paralytic disease and 70 per cent against
any disease, non-paralytic and paralytic 6,9. In Texas, the
protective vaccine efficacy of Salk vaccine was
96 per cent during two polio seasons 31 . The
immunogenicity and protective efficacy of Salk vaccine
have been of very high order in every industrialised
country in which it has been used15,17,32. In their context
the anxiety was about the duration of immunity. The then
widely held belief was that antibody induced by killed
virus antigen would not last long and repeated boosters
would be necessary to sustain protection. The need for
multiple doses of IPV was counted as a disadvantage,
in comparison with OPV, just three doses of which would
give life long immunity according to this view. In reality
the reverse in true - antibody persistence was prolonged
even with the old IPV in the US32 and in developing
countries the number of doses of OPV needed for
ensuring protection was many times more than for
IPV27,33.
Swedish children given three primary and one booster
doses of the old IPV were all antibody positive when
tested 18 yr later32. French children given three plus one
doses of E-IPV remained antibody positive even when
they were adults34. These studies and the vast experience
with IPV in many European countries have shown it to
be an excellent immunogen with prolonged (sustained)
immunity for decades even in the absence of continued
boosters or continued virus circulation to boost antibody
level.
On account of the WHO policy of exclusive use of
OPV in developing countries, there have been only very
few studies conducted on the old or new IPV in such
countires, almost all of which showed excellent antibody
response, in terms of both the seroconversion rates and
antibody titres35-39. We measured the antibody response
of infants to three doses of the old IPV during
1979-198036,37. Since there are three variables
(seroconversion rates) for inter-study comparison, we had
devised a single variable, namely the seroconversion index
(SI), which is the cumulative response of 100 infants to
the three polioviruses, or in other words 300 potential
seroconversions27. In effect the SI would approximate to
the mean of the seroconversion rates to the three types of
polioviruses. In the first study in 67 infants given the
quadruple vaccine containing DTP and the old formulation
IPV, the SI was 94 after three doses given at intervals of
4 wk between doses and 98.5 when the interval was 8
wk between doses36. In comparison the SI after 3 doses
of OPV was only 70-78 in several studies in Vellore
(Reviewed  in  Ref.  27).  In  a  larger study of the
quadruple vaccine given to 152 infants
(6-45 wk old), the SI was 87 when the interval between
doses was 4 wk37. The seroconversion rates in the group
with 8 wk interval between doses were 100, 98 and 95
per cent to types 1, 2 and 3 polioviruses, respectively and
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the immune response to IPV. One was the presence of
maternal antibody when vaccination commenced and the
other was the interval between doses29,30,36,37. The effect
of maternal antibody was negligible if the first dose was
given at or after 8 wk of age.
We collaborated with the department of paediatrics
of the Mysore Medical College (Mysore, Karnataka) in
comparing the antibody response of infants given 3 doses
of either OPV or IPV, in 1987 (Chetna NC and John TJ,
unpublished). The old IPV manufactured by Institute
Merieux in France was used in this study. The number
of children, seronegative to the three poliovirus types
prior to vaccination who completed the study were
49 for OPV and 53 for IPV. Although infants were
eligible to commence immunisation at the age of 6 wk,
in reality all children were over two months when they
received their first dose. The seroconversion rates
induced by OPV were 85, 89 and 55 per cent against
poliovirus types 1, 2 and 3 respectively, for an SI of 76.
The seroconversion rates due to Salk vaccine were 98,
98 and 96 per cent against poliovirus 1, 2 and 3
respectively, with the SI of 97. The Fig. illustrates not
only these differences in seroconversion rates but also
the contrast between the levels of antibody achieved by
the children receiving the two vaccines. The proportions
of children with very high antibody titres (512 or more)
to poliovirus types 1 and 3 in response to Salk vaccine
were indeed higher than the proportions responding to
OPV with titres of 8 or even 4 (Fig.). With E-IPV even
higher antibody titres would be achieved.
Soon after the RIVM began producing E-IPV, we
received the same supplied as quadruple vaccine
containing DTP, for field evaluation. Following just two
doses of E-IPV in infants 6 to 45 wk of age, the
seroconversion rates were 97, 84 and 97 per cent to the
three viruses respectively and the SI was 9429. The
seroconversion rates were better in infants 8 wk of age
and older when the first dose was given than those of
6 or 7 wk of age and also when the interval between
doses was 8 wk instead of 429,30. The SIs achieved by
children given the old IPV (3 doses) or E-IPV (2 doses),
according to the presence or absence of maternal antibody
when the first dose was given, and according to the interval
between doses, are summarised in the Table. Although
not directly tested by us, data from others show that we
could expect near 100 per cent seroconversion to the three
types after a third dose, irrespective of the age of the
infant or the interval between doses.
In Kenya, the seroconversion rates of infants
2 months or older, given two doses of E-IPV were 94,
88 and 97 per cent to the three types and after three
doses 100, 100 and 98 per cent respectively38. The SI
was 93 after 2 doses and 99 after 3 doses38. In Cote
d’Ivoire, where a proportion of infants had remained
seronegative after giving 3 doses of OPV, and in Oman
where many infants had remained non-immune even
after giving 5 doses of OPV, a single suplemental dose
of IPV induced seroconversion in them 2 to 14 times
more frequently than what could be achieved by a
supplemental dose of OPV39,40. Moreover, the IPV
induced superior booster seroresponse in terms of
achieved antibody titres, than did OPV39,40.
While most of the studies in developing countries
showed excellent immunogenic efficacy of IPV, which
was considerably better than that of OPV, there has also
been one study in which the results were in the opposite
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Fig. Antibody responses of infants given three doses of Salk IPV or
OPV at intervals or 4 wk between doses. Only infants without any
poliovirus antibody prior to immunisation were included in the
analysis. The presence of antibody at serum dilution of 1:4 after
immunisation was defined as seroconversion.
8direction41 . The WHO conducted a study of
immunogenic efficacy of OPV and IPV in the Gambia,
Oman and Thailand41. Seroconversion rates could not
be calculated in the Gambia. In Thailand the SI after 3
doses of  OPV  was 95,  but  the  SI  after  3  doses of
E-IPV was only 75. After 2 doses of E-IPV the SI was
only 5641. On the other hand, in Oman the same study
recorded  SI  of  84 after 3 doses of OPV and 94 after
3 doses of E-IPV41. After 2 doses of E-IPV the SI was
7841. The result of the study in Thailand is the one
exception to the finding of markedly higher immunogenic
efficacy of 3 doses of old IPV or 2 doses of E-IPV than
that of 3 doses of OPV documented in every other study.
Obviously there was some reason(s) for the very low
immune response of children to IPV in the study in
Thailand, but there is no scientifically plausible factor to
explain it41.
For obtaining the best results with 2 doses of IPV it
should be given from 8 wk of age or later and the second
dose after an interval of 8 wk or more29,30,38. However,
a booster should be given after some interval. Such a
sequence does not harmonise with the current infant
immunisation schedule of DTP, which is scheduled in
3 doses at 6, 10 and 14 wk of age. Therefore the primary
immunisation could be with 3 doses of IPV in the EPI
schedule. The WHO study in Oman gave the 3 doses of
IPV in the DTP schedule and got excellent
seroconversion rates, namely 90, 96 and 95 per cent to
types 1, 2 and 3 polioviruses respectively, and SI of 9440.
Three doses of OPV given in the same schedule resulted
in only 81, 97 and 73 per cent seroconversion to the
three types and SI of 8440.
Being a purified antigen, the E-IPV could be injected
intradermally in fractional doses without reducing its
immunogenicity, both for primary and for booster
vaccination, thus saving on cost42,43. Intradermal
immunisation has also been shown to induce rapid and
vigorous anamnaestic response in case it were to be
used for outbreak control in an immunised community42,43.
The antibody levels thus achieved were orders of
magnitude higher than that are usually achieved with
OPV, given either in primary or booster vaccinations42,43.
At the present time these observations have only
theoretical importance, but in case data were needed in
the post-eradication era, they are already available.
Protective efficacy of IPV in developing countries: Studies
on vaccine efficacy of IPV in developing countries, in terms
of protection from polio, have been even fewer than the
immunogenicity studies described above. There has only
been one published large-scale study on the clinical
protective efficacy of E-IPV in a developing country,
Senegal44. It showed the field level protective vaccine
efficacy of two doses of E-IPV to be 89 per cent against
paralytic polio44. We had conducted a study using E-IPV
in  one  half  of  the  population  (5 million)  in  North
Arcot  district,  Tamil  Nadu,  India,  on behalf  of  the
Indian  Council  of  Medical  Research (ICMR), during
1987 to 199245 .   IPV was given as DTP-IPV
combined vaccine replacing DPT, in two doses at 2 and 4
months of age, and the third dose was given at 9 months
at the time of measles vaccination. The other half
population was given OPV in the regular schedule. The
objective of the ICMR was to conduct at demonstration
of polio control, including its documentation by disease
and virus surveillance45. The Government gave permission
to conduct the study on condition that the study will not be
published; therefore no details will be recorded here. The
incidence of polio declined in both populations; the rate of
fall was faster and steeper in the IPV area. In the OPV
area the incidence declinsed from 9 to 0.4 per 100,000
population per year in the 5 yr of study, when 95 per cent
coverage had been achieved at the required age interval.
In the IPV area the annual incidence fell from 14 to 0.3
per 100,000 when  84 per cent coverage had been
achieved45.
Earlier we had conducted a small study of field level
vaccine efficacy of IPV in a rural community of 50,000
population, from April 1980 through March 1983.
Quadruple vaccine (DPT-IPV) was given to infants in
the routine schedule, at first using the old IPV and later
using the E-IPV. Among 3220 vaccinated children
observed for 6911 child-years, none developed polio27,46.
In the adjacent area, with 50,000 population, 3104 children
had received DPT, and were observed for 6612 child-
years; 17cases of polio were recorded among them27,46.
The vaccine efficacy was 100 per cent. A much larger
study, was conducted by Renu Patel in Mumbai, during
1988 through 199147 (Patel R, personal communication).
As Professor of paeditrics in Grant Medical College,
she was in charge of the Integrated Child Development
Scheme in several slums in Mumbai. Frustrated with
the persisting occurrence of polio in spite of achieving
over 90 per cent coverage with 3 doses of OPV in infants,
she introduced Salk IPV in one population unit of about
100,000 people, in 1988. From 1989 no child developed
polio in that population. Earlier, annually about 5 children
would get paralysed, and all of them were recipients of
at least 3 doses of OPV. In 1989 she expanded the IPV
population to another block of about 100,000 and again
polio disappeared in that block from 1990. In that year
one more block was included under IPV immunisation,
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first block remained polio-free over 3 yr, the second block
was polio-free for 2 yr and the third bock for one year,
while under IPV coverage. At that juncture she was
transferred out of Mumbai and the study could not be
continued47 (Patel R, personal communication).
In summary, there is sufficient evidence to show not
only that IPV is highly immunogenic in developing
countries but also to show that its protective efficacy is
much superior to that of OPV including in those countries
in which OPV provides low immunogenic and protective
efficacy.
Does IPV induce mucosal immunity?: It had been widely
taught, and stated in many textbooks that IPV induced
no mucosal immunity and for that reason it was unsuitable
for use in developing countries under the EPI as it would
not control its incidence. According to this viewpoint,
while humoral immunity induced by IPV is sufficient for
personal protection, the lack of mucosal immunity would
not protect against infection with wild polioviruses. Unless
infection is prevented in the vaccinated, the transmission
of the pathogen in the community will not be retarded.
Unless transmission is reduced, vaccination programme
will not get the benefit of herd effect, necessary to control
infection and disease. The conclusion of this argument is
that only OPV, which is supposed to induce both humoral
and mucosal immunity, is suitable for prevention, control
and ultimately elimination of poliovirus infection in
developing countries. Facts do not agree with his
contention.
There are two aspects to mucosal immunity. One is
the presence of mucosal secretory immunoglobulin A
(IgA) and the other is the inhibitory effect on mucosal
infection upon exposure to infection. A common error
has been to equate one with the other. Indeed mucosal
infection due to vaccine viruses in OPV would induce
mucosal secretory IgA, but the non-infectious vaccine
given parenterally would also induce it, albiet not so often
or in comparable amounts. Mucosal IgA in response to
local infection is neither the only nor the major constituent
contributing to inhibition of mucosal infection when
exposed. There are other factors in mucosal immunity,
particularly if we define it as inhibition of mucosal
infection of wild polioviruses when exposed, as a result
of any immunisation, rather than the level of IgA. This
will be evident in the following paragraphs.
To begin with, it is important to point out that direct
mucosal stimulation is not necessary for the presence of
secreted antibody on mucosal surfaces. Poliovirus
neutralising antibodies are secreted in human breast milk
of immune mothers, and continue to be secreted as long
as lactation continues48,49. The interesting correlation is
that the presence of poliovirus-neutralising antibody in
human breast milk is determined by the height of antibody
level in the serum48,49. In other words, local/mucosal
immunity is a reflection of the height of past immune
response, rather than direct mucosal stimulation48,49. It
was stated earlier that IPV induces much higher levels of
antibodies than OPV. Indeed, secretory IgA response in
breast milk has been demonstrated as a response even to
the non-replicating antigens in IPV50.
Functional mucosal immunity against wild polioviruses
has a spectrum of expression, ranging from a mere
reduction in the quantum or duration of virus shedding,
to complete resistance to reinfection. It cannot be directly
measured since it is unethical to challenge immunised
children with wild poliovirus. Therefore mucosal immunity
to vaccine viruses has been taken as a surrogate. Passive
immunisation due to maternal antibody in infants reduces
the frequency of vaccine virus take when the antibody
titres are very high, showing again that serum antibody
levels determine mucosal protective immunity51.
Mucosal antibody induction by IPV has been
investigated by a few researchers52-55. All studies
reported the induction of secretory IgA by IPV. After
giving two doses of E-IPV to infants, nasopharyngeal
virus-specific IgA was detected in 57-65 per cent to
type 1 poliovirus, in 62-77 per cent to type 2 and 60-71
per cent to type 354. After three doses, 89 per cent had
IgA specific for types 1 and 3 polioviruses and 91 per
cent had it for type 254. For comparison, 73-77 per cent
of infants had such antibody after taking two doses of
OPV and 100 per cent had IgA after three doses54 .
Moreover, the IgA levels were higher in infants given
OPV than IPV54. Nasopharyngeal virus neutralising
antibody to poliovirus types 1, 2 and 3 was found in 28,
42 and 49 per cent of infants after two doses of E-IPV
and in 43, 60 and 66 per cent after three doses,
respectively. On the other hand, 73-77 per cent infants
had such activity after two doses of OPV and 100 per
cent had it after three doses54.
In one study of children in the USA53, who had earlier
received OPV or IPV had equal frequency and levels of
secretory IgA antibodies both in the pharynx and in stools,
thereby indicating that there is little to show one is superior
to the other. In industrialised countries, both OPV and
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IPV immunise with the same frequency. In the developing
country context 3 doses of OPV immunise only one half
to two-thirds of children against poliovirus types 3 and 1;
mucosal immunity can only develop in these children. On
the other hand, 3 doses of IPV immunise over 95 per cent
of children, and even slightly reduced frequency of mucosal
immunity will be numerically superior to that of OPV. The
usual teaching that IPV does not induce mucosal immunity
and that it is not suitable for controlling polio in developing
countries is not based on a scrutiny of evidence, but on
assumptions believed by many to be true by repeated
assertions, quoted in many textbooks and papers56-59.
In the early years several workers had given OPV
or the old IPV to children and later challenged them
with OPV. In general, children who were naturally
immune (due to earlier wild virus infection) had most
gut immunity, OPV-immunised had somewhat less, IPV-
immunised had still lower and non-immune children had
the least degree of gut immunity54. In one study54, two
groups of infants, given two doses of either OPV or E-
IPV, were challenged with a dose of OPV. In the OPV
group 13 per cent (3/23) and in the IPV group 20 per
cent (4/20) shed vaccine virus(es) in the stools, indicating
mucosal immunity of a comparable degree induced by
both vaccines. In another study, when the challenge dose
of vaccine virus was high, pharyngeal shedding was
inhibited more frequently in IPV immunised children, than
in OPV-given children53. When the challenge dose was
low (nearer to natural events), inhibition was complete
in both groups of children53. Since oral-oral/respiratory
route is the more common for transmission of wild
polioviruses, the strong pharyngeal mucosal immunity
induced by IPV explains the strong ‘herd effect’ in
developed as well as developing country settings60.
The WHO study in the Gambia, Oman and
Thailand41 had investigated mucosal immunity after
immunisation, by challenging with a dose of monovalent
OPV type 1 and testing a stool sample for virus shedding
after a week. In Oman 13 per cent of children who
had earlier received 4 doses of OPV shed virus, but
only 10 per cent did so after getting 3 doses of IPV,
thereby showing that there was no difference in mucosal
immunity between the two vaccines41. In contrast, in
Thailand 57 per cent of children who had received 3
doses of IPV shed virus, while ony 14 per cent of those
who had got 4 doses of OPV shed virus after challenge41.
In the Gambia 4 per cent of children vaccinated with 4
doses of OPV, 9 per cent of children vaccinated with 4
doses of OPV and 3 doses of IPV and 16 per cent of
children vaccinated with 3 doses of IPV shed the
challenge virus41. If the frequency of shedding of
challenge virus is taken to reflect mucosal immunity
due to IPV it would appear that there was good mucosal
immunity in Oman, no mucosal immunity in Thailand
and intermedia te level in the Gambia. The difficulty of
interpreting the results of such experiments in developing
countries includes the widely variable frequency of
vaccine virus take (and shedding) in different geographic
locations. Unless the median infectious dose (MID) is
measured and a fixed and predictable infectious dose
such as 10 or 100 MIDs is used for challenge, the true
differences in virus shedding accounted by mucosal
immunity, as against the naturally occurring inhibitory
factor(s) influencing the low vaccine virus take after a
dose of OPV, cannot be measured with any degree of
confidence.
We had conducted just that kind of a study, not in
children for obvious reasons, but in Macaca radiata
monkeys, which are an excellent experimental animal
model for gastrointestinal poliovirus infection61. After
immunising animals with 3 doses of the old IPV, groups
of four animals were challenged with 100 MIDs of wild
poliovirus type 1 at various intervals from the time of the
third vaccine dose. While every unimmunised control
animal got infected and shed virus in the throat and
faeces, no vaccinated animal did, when challenged
between 4 and 12 months after vaccination, thereby
clearly demonstrating the phenomenon of mucosal
protective immunity induced by IPV61.
Mucosal immunity, either due to secretory antibody
or ‘spill over’ of IgG antibody, is a feature in many cases
of parenteral vaccination with non-replicating antigen,
against diseases caused by mucosal infections. The
vaccine we use against diphtheria is a toxoid, and the
immunity induced is basically humoral, ‘anti-toxin’ in
specificity, not anti-bacterial. Yet, vaccination of children
results in decline in the incidence of disease in the
community. Humoral immunity somehow contributes to
a degree of mucosal immunity, sufficient to reduce
infection or at least the quantum and/or duration of
bacterial shedding by the vaccinated children. Vaccines
against pertussis contain either killed whole bacteria or
specific immunogens without bacteria (hence called
acellular). The herd effect of the killed vaccine had been
well recognised for decades. The acellular pertussis
vaccine offers protection against infection among family
members of the vaccinated children, thereby indicating
mucosal immunity in the vaccinated62. Current influenza
vaccines are sub-units of inactivated influenza viruses,
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and even they cause substantial reduction in virus
transmission from the vaccinated, herd effect in other
words, thus showing evidence for mucosal immunity
resulting in reduced frequency of infection or of virus
shedding63-65. Vaccination of staff caring for elderly
people has been shown to reduce influenza morbidity
and mortality among the elderly63,64. In one study, the
reduction of disease was 68-87 per cent among patients
exposed to staff with high vaccination coverage65. Even
more convincing has been the mucosal immunity induced
by vaccines against Haemophilus influenzae type b
(Hib)66. The immunogen in these vaccines is the capsular
polysaccharide, given by injection. Among all vaccines,
mucosal and parenteral, against various diseases, Hib
vaccine is perhaps the one with best herd effect66.
The general principle can now be enunciated that all
parenteral vaccines exhibit herd effect due to mucosal
immunity, provided (i) they offer good immunogenicity
and individual protection; (ii) the disease in question is
due to mucosal infection by human-to-human transmitted
pathogen, irrespective of the tissues or organs affected
by pathology; and (iii) mucosal immunity is not defined
narrowly as secretory IgA. There has been no
observation or reason to believe that IPV alone is an
exception to this general principle.
Herd immunity and herd effect induced by IPV: Herd
immunity and herd effect have recently been redefined67.
The reduction of incidence of infection or disease as the
case may be, in the unvaccinated segment of a population
as a result of vaccinating a proportion of that population
is herd effect67. Herd immunity on the other hand is the
proportion of immune subjects in a defined population67.
Herd effect results from the reduction of transmission
of the pathogen to the unvaccinated, on account of the
retardation of transmission from the vaccinated, due to
the induced immunity. Thus herd effect is a reflection of
both herd immunity and the inhibitory effect of vaccine-
induced immunity on the shedding of the pathogen
necessary for new infections to occur. In order to induce
immunity to inhibit infection or shedding of the pathogen,
the vaccine must have high immunogenicity. Absent or
reduced shedding is a reflection of mucosal immunity,
which prevents infection or reduces the quantum and/or
duration of shedding. Thus, herd effect is manifest due
to the development of mucosal immunity67. For obvious
reasons herd effect occurs only in infections transmitted
human to human, like polioviruses among many others
described in the earlier section67.
When vaccination is introduced, the incidence of a
disease will decline in parallel with the proportion protected
– the proportion being the product of vaccine coverage and
vaccine efficacy merely on account of the herd immunity
induced by vaccination. This decline is confined to the
vaccinated individuals. If the decline of incidence is steeper,
which could happen only if the incidence in the unvaccinated
segment also declines, then it is a reflection of herd effect of
the vaccine 27. From 1955, the year the Salk vaccine was
introduced in the USA, until 1962 when the national policy
shifted to OPV, the incidence of paralytic polio had declined
by about 95 per cent, far in excess of the proportion of
susceptible persons vaccinated9. The incidence of polio
declined in excess of coverage, both at the national level
and in particular in specific regions where focussed studies
were conducted9,68-70. It is not widely appreciated that the
rate of decline in incidence remained about the same even
after introducing OPV in 1962, indicating that the herd effect
of IPV was not inferior to that of OPV in the USA until
1965, by which time more than 99 per cent reduction in
incidence had already occurred68-70. Even less appreciated
is the fact that from 1961 till 1965 the coverage of preschool
children with 3 doses of IPV had only gradually declined
from 74 to 50 per cent while that of OPV increased from 6
per cent in 1962 to 47 per cent in 196468-70. In other words,
more than 99 per cent reduction of incidence of polio had
actually occurred in the US mainly under the influence of
IPV and its herd effect.
The WHO had investigated the performance, safety
and efficacy of OPV and IPV in several European countries
and concluded that IPV offered both personal protection
and community protection (reflecting herd effect)71. In
Finland, the IPV coverage was low at about 18 per cent
by 195915,16. In 1960-61, mass vaccination was given and
as the total population coverage with
3 doses reached 51 per cent, polio disappeared in the entire
population16. The herd effect of the early and relatively
crude (according to modern standards) IPV was quite
obvious and remarkable in both USA and Finland. Another
demonstration of high herd effect of Salk vaccine was in
the Netherlands, in which a particular religious community
of 200,000 people, living well dispersed throughout the
country, had refused vaccination9,72-74. Two outbreaks of
polio had occurred among them, first by type 1 virus (1978,
110 cases) and later by type 3 virus (1992, 71 cases)9,72-74.
Even though the viruses had circulated widely in that
religious community, only one case of polio had occurred
outside their members and there was no laboratory
evidence of virus dissemination among the general
population9,70-73. Even the estimated 400,000 unvaccinated
individuals remained unaffected9,72-74.
We conducted a field study to investigate the herd
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effect of IPV27. The hypothesis was that IPV would
not retard the infection rate of polioviruses if it did not
induce any mucosal protection of vaccinated children.
On the contrary, if the circulation of viruses were to be
retarded, it would mean that mucosal immunity was
induced. A rural community was chosen and from July
1979, weekly stool samples were collected from all
infants. They were continued in the study until they were
three years of age. Infants born from January 1980 were
also similary investigated, but were given three doses of
Salk vaccine, starting at 3 months of age. The former
group of 94 was the control population, from whom 4527
stool samples had been collected. From the vaccinated
group, or the study population of 82 children, 8159 stool
samples were collected. The reason for lower number
of stools in the control group was that their samples were
not collected prior to July 1979. The stools were examined
for the presence of polioviruses and we found that rate
of virus shedding was 1.52 per cent in the control and
only 0.52 per cent in the vaccinated group. This difference,
attributable to vaccination, was statistically highly
significant (P<0.001)27.
It was stated earlier that herd effect of a parenteral
vaccine was dependent upon the degree of
immunogenicity. This is illustrated by the experiences in
Finland and Belgium15,16,75. In Finland, where a nation-
wide three-dose IPV campaign reached 51 per cent
coverage, the disease (and infection) disappeared16. In
Belgium, on the other hand, where only two doses of
IPV were given by campaign, even 75 per cent coverage
did not result in interruption of wild virus transmission75.
In both countries the same vaccine was used, but the
immunogenicity of three doses was superior to that of
two doses, as had been shown earlier.
India’s policy decision to manufacture IPV and its
reversal: India launched the EPI in 1978 and introduced
OPV in 1979. During the next 10 yr, the reported annual
number of cases of polio did not decline, obviously due
to inadequate vaccine efficacy of OPV. The various
studies on IPV conducted in India were to stimulate and
encourage the Government make an informed choice
on polio control using OPV or IPV or both. Yet, IPV
was not licensed in India, except for limited research
investigations.
In 1988, after deliberations within the scientific
community in India, the Government took a new policy
decision to produce E-IPV in India and make it available
to the nation by 1991. The intention was to make available
sufficient IPV for polio control, and to use it side by side
with OPV so that experience with both vaccines could
be evaluated and compared subsequently. The IPV
manufacturing unit was built in Gurgaon, under the name
Indian Vaccine Corporation Limited (IVCOL), funded
by the Department of Biotechnology. The training of
professional staff and the transfer of technology for
vaccine production in large volume bioreactors, using
van Wezel’s microcarrier cell culture method, were
offered as a gift from the Government of France. The
mandate of IVCOL was to use the microcarrier
technique to manufacture IPV, inactivated rabies vaccine
and live attenuated measles virus vaccine. The intention
was to obtain the microcarrier cell culture technology,
vaccine quality Vero cells, and to become self-sufficient
for various vaccines. It had been deemed unethical to
inject sheep brain rabies vaccine in humans and IVCOL
would have produced sufficient safe rabies vaccine to
replace sheep brain vaccine by 1991. The potential for
export of all three vaccines to earn foreign exchange to
strengthen our economy was another motivation. Since
the Governments of India and France covered the
development investment, the vaccines made here would
have been extremely competitive in price in the world
market and quite cheap within the country, especially
for use in national programmes. However, it appears
that the Ministry of Health and Family Welfare declined
to license IPV in the country and therefore the initiative
was effectively blocked. By the end of 1991, the
Government rescinded its earlier policy decision to
introduce IPV also in India and decided to close down
IVCOL.
Earlier attention was drawn to the fact that the
Government had closed down the one successful OPV
manufacturing unit in India; now history was repeated by
closing the IPV manufacturing unit also. The ultimate
beneficiaries of these decisions were vaccine
manufacturers outside India and vaccine importers within
India. But those who suffered the consequences were
the hundreds of thousands of children who developed polio
paralysis in spite of taking the 3 doses of OPV under the
Government programme and also the economically weak
members of society who suffered the adverse reaction of
encephalomyelitis caused by sheep brain rabies vaccine.
Unfortunately, neither group of victims was compensated.
Cost was certainly not the constraint since we have closed
down the IPV manufacturing unit, incurring huge loss, a
national waste. Our polio and rabies vaccine policies were
not driven by science.
The future prospects on IPV in the global setting: During
the last decade several industrialised nations have
discontinued the use of OPV in favour of the exclusive
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use of IPV. This trend was set by France, which had
given the option to medical professionals to use either
vaccine. The popularity of IPV increased steadly and
eventually France discontinued the use of OPV. Very
soon the country eliminated indigenous wild virus polio,
transmission of imported wild polioviruses from African
countries and also vaccine-induced polio76,77. Germany,
USA and Canada also abandoned OPV primarily to avoid
vaccine-induced polio78,79. Currently some 25 countries
in Europe, North America and the Pacific use only IPV
and each year more rich countries are opting for IPV
(Wood D,  personal communication). Some countries
have had to wait two or more years after deciding to
switch to IPV in order for the manufacturers to upscale
production. European countries prefer combination
vaccines containing IPV, such as DTP-IPV or DTP-
Hepatitis-B-IPV while the US uses IPV not combined
with other vaccines78,79. The major reason for switching
to IPV in developed countries is to avoid OPV-associatd
polio in vaccinated children and also in family and
community contacts.
The demand for IPV is increasing steadily among
rich countries, but no new manufacturers have begun
marketing IPV. Consequently the selling price of IPV is
exorbitant and remains unaffordable to low and medium
income countries. Thus, the disparity based on the income
level of countries, namely rich countries opting for the
completely safe IPV while poor countries having to be
satisfied with OPV with its attendant risk of vaccine-
associated polio is being prepetuated. Neither the World
Health Organization nor the Government of India has
altered their policy to use OPV exclusively. Without
articulating a shift in policy, indicating the expansion of
the market for IPV, manufacturers would be reluctant
to invest money in new plants to produce it. Fortunately
there seems to be new developments in this direction.
Some manufacturers have been attempting to prepare
IPV using Sabin vaccine viruses as the base, instead of
laboratory-maintained fully neurovirulent wild-virus
stocks.
The annual numbers of OPV-induced polio in India
are in the range of 100-200 cases80,81. This is considered
to be unethical by some, especially as a safe and effective
alternative vaccine is already available in the world.
Others consider this as an acceptable price for preventing
a much larger burden of wild virus polio. The future
perspective on the need, potential and wider use of IPV
is likely to be an evolving scenario as more Public Health
and opinion leaders become aware of the issues involved.
In addition to causing OPV-associated polio
sporadically, a new risk of the continued use of OPV
has come to light recently. Contrary to common belief,
the vaccine virues in OPV are poorly transmitted from
the vaccinated to the unvaccinated. However, by genetic
mutations and probably genetic recombination with other
enteroviruses, vaccine virus may revert to its original
parental quality of easy transmissibility, thus giving rise
to fully neurovirulent circulating vaccine-derived but wild-
like viruses that are virtually no different from wild
polioviruses except that they come from the vaccine
lineage of ancestry82-84. Such revertant viruses are called
‘circulating vaccine-derived polioviruses’ (cVDPV)82-84.
Four such incidents of the emergence of cVDPV have
been detected, two with large-scale outbreaks of infection,
prolonged circulation over a few to many years causing
at  least  20 to 30 cases of polio among children82-84,
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Table.  Seroconversion  indices  according  to  the  presence  or  absence of  maternal  antibody  at  the  commencement  of   vaccination,  and
the interval between doses
Vaccine Maternal antibody Interval between doses (wk)
4 8
Present 66 95
Old IPV (3 doses) Absent 95 99
E-IPV (2 doses) Present 87 87
Absent 96 96
IPV- inactivated poliovirus vaccine
E-IPV - enhanced potency IPV
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(Wood D, personal communication 2003). The continued
use of OPV perpetuates this risk. Its cessation is also
believed to be fraught with the risk of emergence of such
wild-like properties, as there will be a period of time when
children who shed vaccine progeny viruses and fully
susceptible infants would mix in the community, providing
the milieu for transmission of vaccine-derived viruses to
unvaccinated children and possibly starting the process
of the emergence of cVDPV. The porbability of this
risk is unknown. If we were to assume that the
probability is very low and discontinue OPV, it may take
two to three years of intense surveillance before we
may detect cVDPV causing clinical polio. By then the
virus could have disseminated silently to wide geographic
regions, thereby jeopardising the achievements of polio
eradication. For these reasons there is current ongoing
deliverations on the best way to manage the final phase
of global eradication of polio. The safest option appears
to be to reach the goal of elimination of wild virus
transmission, to introduce IPV and then to replace OPV
with IPV in order to prevent or intercept the emergence
of cVDPV 85 . According to this viewpoint, polio
eradication must be perceived as truly the zero incidence
of poliovirus infection, both wild and vaccine-derived, in
developed and developing countries86.
Summary and conclusions : Significant progress has
been achieved to prevent, control and even eliminate
polio due to wild polioviruses in countries and continents
during the 50 yr after the design and development of a
safe and effective vaccine by Jonas Salk. We have two
excellent vaccines, IPV and OPV, but the unsavoury
arguments about their merits and defects had led to delays
in controlling the disease in endemic countries and in its
ultimate eradication. The peculiar circumstances of the
early history of the development of IPV had a major
role in its rejection by the USA once the live attenuated
OPV became available. That policy shift in the USA
had major impact on the vaccine policies of the WHO
and many member countries like India.
The original Salk vaccine was further improved by
van Wezel in the Netherlands. This new formulation,
then called as E-IPV, is currently the only one in the
market. Therefore, today the name IPV denotes this
improved version with enhanced and standardised
potency. It is a completely safe and highly effective
vaccine against poliomyelitis in children. Contrary to
common teaching without scrutiny of evidence, it confers
excellent mucosal immunity in vaccinated children and
provides a high degree of herd protective effect in the
community. These properties are expressed both in
developed and in developing countries, unlike OPV which
has reduced efficacy in polio endemic tropical countries.
The reason for developing countries not making use of
this excellent choice has more to do with policies
recommended by the WHO than on science or
economics. The cost of production of IPV is only slightly
more than that of OPV, but the selling price is exorbitantly
high due to the market forces of high demand from rich
countries and inadequate supplies even to meet the current
requirements. Having reached the verge of global
eradication of wild polioviruses using IPV by some
countries and OPV by many, including India, the future
course is not clear on account of some potential problems
of genetic reversion inherent to the nature of OPV. We
have difficult choices ahead of us in terms of the risks,
benefits and economics of pursuing the current policy or
of altering it. If chosen, IPV will perform well – that is
one important message of this review.
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